Treatment of nephrogenic systemic fibrosis with Re-PUVA

Journal of the American Academy of Dermatology

Volumn 59, Issue 2 SUPPL., 2008, Pages

  Duffy, Keith L ^a   Green, Layne ^a   Harris, Ronald ^a   Powell, Douglas ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; GADODIAMIDE;

ADULT; ARTICLE; CASE REPORT; FEMALE; FIBROSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; PUVA; TREATMENT OUTCOME;

ACITRETIN; FIBROSIS; HUMANS; KERATOLYTIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PUVA THERAPY; SKIN DISEASES;

EID: 46749159259     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.08.035     Document Type: Article

References (5)

1. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., and LeBoit P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 365 (2000) 1000-1001
2. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
3. USFDA Healthcare professional sheet - Gadolinium-containing contrast agents for Magnetic Resonance Imaging (MRI) FDA alert 06/2006. Development of serious and sometimes fatal nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. Available at: www.fda.gov/cder/drugInfoSheets/HCP/gccaHCP.htm.
4. Brenner M., Herzinger T., Berking C., Plewig G., and Degitz K. Phototherapy and photochemotherapy of sclerosing skin diseases. Photodermatol Photoimmunol Photomed 21 (2005) 157-165
5. Lauchli S., Zortea-Caflisch C., Nestle F.O., Burg G., and Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208 (2004) 278-280